Overview
Ketamine and transcranial magnetic stimulation (TMS) are two of the most prominent alternatives to conventional antidepressants for patients with treatment-resistant depression (TRD). Both have emerged from decades of research into novel depression treatments, and both offer distinct mechanisms of action that differ fundamentally from SSRIs, SNRIs, and other monoamine-based therapies. However, they differ dramatically in their approach, speed, delivery, side effect profiles, and practical considerations.
What Is TMS?
Transcranial magnetic stimulation uses focused electromagnetic pulses to stimulate nerve cells in specific brain regions. During a TMS session, a magnetic coil is placed against the patient's scalp over the left dorsolateral prefrontal cortex (DLPFC) — a brain area consistently associated with mood regulation and commonly underactive in depression. The coil generates brief magnetic pulses that pass through the skull and induce small electrical currents in the underlying cortical tissue, activating neurons in the targeted region.
The FDA first cleared repetitive TMS (rTMS) for treatment-resistant depression in 2008, and subsequent approvals have expanded its indications. Newer protocols, including intermittent theta burst stimulation (iTBS), allow shorter session times — as brief as three minutes — while maintaining comparable efficacy to conventional TMS protocols that require 20 to 40 minutes per session.
Mechanism of Action
Ketamine works pharmacologically by blocking NMDA receptors in the glutamatergic system, triggering a cascade that includes glutamate release, AMPA receptor activation, BDNF release, mTOR pathway activation, and rapid synaptogenesis. It is a systemic pharmacological intervention — the drug circulates throughout the brain and body.
TMS works through neuromodulation — the direct electromagnetic stimulation of neural circuits. Repeated stimulation of the DLPFC increases cortical excitability and normalizes activity in mood-regulating circuits, including the DLPFC's connections to the anterior cingulate cortex, amygdala, and other limbic structures. Over the course of treatment, this repeated stimulation produces lasting changes in neural connectivity and function. TMS does not involve any drug and produces no systemic pharmacological effects.
Treatment Protocol
Ketamine treatment typically begins with an acute series of four to six sessions over two to three weeks. IV infusions last approximately 40 minutes, with an additional one to two hours of monitoring. Oral and sublingual formulations used in at-home protocols follow varying schedules as prescribed by the clinician. After the acute phase, maintenance sessions may be scheduled weekly, biweekly, or monthly depending on individual response.
TMS requires a significantly greater time commitment in the acute phase. Standard rTMS protocols involve daily sessions (Monday through Friday) for four to six weeks — a total of 20 to 30 sessions. Each session lasts 20 to 40 minutes for conventional rTMS, or as few as three minutes for iTBS protocols. The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol condenses treatment into five days of multiple daily sessions, though this intensive approach is not yet widely available outside research settings.
Onset of Action
Ketamine produces measurable antidepressant effects within hours of a single treatment, with response often apparent after the first or second session. This rapid onset is one of ketamine's most distinctive clinical advantages.
TMS typically requires two to four weeks of daily treatment before patients notice significant improvement. Some patients begin to respond after the first week, but full response often develops gradually over the four- to six-week treatment course. This timeline is comparable to the onset of SSRIs, though the mechanism is entirely different.
Efficacy
Ketamine demonstrates response rates of 50 to 70 percent and remission rates of 25 to 40 percent in TRD populations. These figures are derived from numerous clinical trials using the standard 0.5 mg/kg IV protocol. Effects from a single treatment are typically transient (lasting days to about two weeks), necessitating repeated treatments.
TMS produces response rates of approximately 50 to 60 percent and remission rates of 30 to 35 percent in TRD, based on large randomized controlled trials and real-world effectiveness studies. One advantage of TMS is that the benefits achieved during the acute treatment course tend to be more durable — many patients maintain improvement for months after completing treatment, with some requiring periodic "booster" sessions.
Side Effects
Ketamine produces transient dissociation, dizziness, nausea, perceptual changes, and mild blood pressure elevation during and shortly after treatment. These effects resolve within one to two hours. Patients cannot drive after treatment and require monitoring. Concerns about misuse potential and long-term effects with chronic use (including possible bladder and cognitive effects) are areas of ongoing research.
TMS has a notably mild side effect profile. The most common complaints are scalp discomfort or pain at the stimulation site and headache, both of which typically diminish over the course of treatment. There is no sedation, no cognitive impairment, and no systemic pharmacological effects. Patients can drive immediately after treatment and return to normal activities. The most serious risk — seizure — is extremely rare, occurring in fewer than 1 in 10,000 sessions.
Cost and Insurance Coverage
Ketamine IV infusions typically cost $300 to $800 per session, and most insurance plans do not cover off-label IV ketamine. Compounded oral formulations are less expensive. The branded esketamine nasal spray has some insurance coverage for TRD but carries high out-of-pocket costs.
TMS is FDA-cleared for TRD and is covered by most major insurance plans, including Medicare, when documentation demonstrates failure of adequate antidepressant trials. A full course of TMS (20 to 30 sessions) may cost $6,000 to $12,000 without insurance, but insured patients may pay only their standard copays or coinsurance.
Patient Experience
Ketamine treatment is a pharmacological experience. Patients typically report altered perception, a dreamy or floating state, and sometimes vivid mental imagery during IV infusions. Some find this experience therapeutic in itself; others find it uncomfortable. Treatment sessions are relatively brief (40 minutes for IV, plus monitoring), and courses are short (six sessions over two to three weeks).
TMS is a non-pharmacological experience. Patients sit in a chair while the magnetic coil delivers pulses to their scalp. They may hear clicking sounds and feel a tapping sensation. There is no altered state of consciousness — patients can read, watch videos, or converse during treatment. The main burden is the daily commitment over four to six weeks, which can be challenging for patients with work or family obligations.
Combining Ketamine and TMS
Some clinicians use ketamine and TMS in sequence or combination. A patient might receive ketamine for rapid relief of acute symptoms while beginning a TMS course, using ketamine as a bridge until TMS effects emerge. Others have explored concurrent administration, though research on combined protocols is still limited. The two treatments target different mechanisms and are not contraindicated together.
References
- Efficacy and Safety of TMS for Depression: A Systematic Review — Berlim et al. (2014), Psychological Medicine. Meta-analysis of TMS efficacy.
- Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) — Cole et al. (2020), American Journal of Psychiatry. The intensive TMS protocol study.
- Ketamine vs TMS for Treatment-Resistant Depression — Comparative review of non-pharmacological and pharmacological approaches.
- FDA TMS Device Clearance Information — FDA regulatory information on TMS devices.
- NIMH Brain Stimulation Therapies — National Institute of Mental Health overview of neuromodulation treatments.
Verdict
Both ketamine and TMS represent non-traditional approaches to treatment-resistant depression that work through different mechanisms than conventional antidepressants. Ketamine offers much faster onset (hours vs weeks) and a different side effect profile, while TMS is non-invasive, non-pharmacological, FDA-cleared, and more widely covered by insurance. TMS requires a substantial time commitment (daily sessions for four to six weeks), whereas ketamine treatment courses are shorter but may require ongoing maintenance. The choice between them often depends on urgency, insurance coverage, patient preference, and clinical history.
Share